Home › Diffuse Large B-Cell Lymphoma › North Carolina › Greenville
Diffuse Large B-Cell Lymphoma clinical trials in Greenville, NC
4 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Greenville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- East Carolina University ( Site 0159), Greenville
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 3
- East Carolina University, Greenville
Registry of Older Patients With Cancer
RecruitingObservational study
- East Carolina University, Greenville
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 2
- Brody School of Medicine at East Carolina University, Greenville
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Nashville, TN15 studies
- Portland, OR15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
Other studies in Greenville
- Acute Myeloid Leukemia10 studies
- Sickle Cell Disease9 studies
- Heart Failure6 studies
- Idiopathic Thrombocytopenic Purpura6 studies
- Blood Disorders5 studies
- Chronic Lymphocytic Leukemia5 studies
- Burkitt Lymphoma5 studies
- Obesity5 studies
- Type 2 Diabetes5 studies
- Autoimmune Diseases4 studies
- High Blood Pressure4 studies
- Myeloproliferative Neoplasms4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.